Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

HER2 dual-blockade combined with aromatase inhibitors (AI) is a promising strategy to improve progression-free survival (PFS) in hormone receptor (HR) positive, metastatic breast cancer (MBC). Pyrotinib is a n...

Source: BMC Cancer - July 13, 2020 Category: Cancer & Oncology Authors: Changjun Wang, Yan Lin, Yidong Zhou, Feng Mao, Hanjiang Zhu, Jinghong Guan, Xiaohui Zhang, Songjie Shen, Xin Huang, Chang Chen, Ru Yao, Jialin Zhao and Qiang Sun Tags: Study protocol Source Type: research